EGFR and non-small cell lung carcinoma: The U.S. Food and Drug Administration (FDA) has approved Mobocertinib and Amivantamab for the treatment of late-stage or metastatic non-small cell lung cancer patients with EGFR ex20ins mutations (28, 29).